May 20, 2017 8 30 AWST
This event has now ended:

Mainstreaming Ovarian Cancer Genetic Testing

Mainstreaming Ovarian Cancer Genetic Testing

This in-service was developed by the Mainstreaming Working party of the Clinical Oncology Society of Australia (COSA) Cancer Genetics Special Interest Group.  It is part of a clinical training initiative introducing ‘mainstreaming’ of genetic testing for women with high-grade non-mucinous ovarian cancer. ‘Mainstreaming’ refers to genetic testing being offered by non-genetics oncology health professionals, to enable more widespread genetic testing of women with ovarian cancer who meet current criteria. A representative of each of the invited groups (medical oncologists, gynae-oncologists and chemotherapy/gynae-oncology nurses) will present a review of current practice in treatment and management of high-grade serous ovarian cancer in Western Australia. Guest speaker Natalie Percival will  provide first-hand experience of the role of oncology nurses in the BRCA testing pathway. She will discuss her experience with mainstreaming at the Royal  Marsden Hospital in London, and how this can be applied within oncology departments in Australia Following completion of the in-service, medical oncologists and gynae-oncologists will be able to directly order BRCA1/2 genetic testing through PathWest Diagnostic Genomics for women with high grade non-mucinous ovarian cancer
More about the event:
For any information or questions please view our FAQ's and support page

FAQ & Support

Show FAQ